| Literature DB >> 27891513 |
Jinfan Tian1, Yue Liu2, Xiantao Song1, Min Zhang1, Feng Xu1, Fei Yuan1, Shuzheng Lyu1.
Abstract
Background. Insufficient data are available on the potential benefit of selective aspiration and clinical predictors for no-reflow in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) adjunct with aspiration thrombectomy. Objective. The aim of our study was to investigate clinical predictors for insufficient reperfusion in patients with high thrombus burden treated with PPCI and manual aspiration thrombectomy. Methods. From January 2011 till December 2015, 277 STEMI patients undergoing manual aspiration thrombectomy and PPCI were selected and 202 patients with a Thrombolysis in Myocardial Infarction (TIMI) thrombus grade 4~5 were eventually involved in our study. According to a cTFC value, patients were divided into Group I (cTFC > 40), namely, insufficient reperfusion group; Group II (cTFC ≤ 40), namely, sufficient reperfusion group. Results. Univariate analysis showed that hypertension, multivessel disease, time from symptom to PCI (≧4.8 hours), and postaspiration cTFC > 40 were negative predictors for insufficient reperfusion. After multivariate adjustment, age ≧ 60 years, hypertension, time from symptom to PCI (≧4.8 hours), and postaspiration cTFC > 40 were independently associated with insufficient reperfusion in STEMI patients treated with manual aspiration thrombectomy. Upfront intracoronary GP IIb/IIIa inhibitor (Tirofiban) was positively associated with improved myocardial reperfusion. Conclusion. Fully identifying risk factors will help to improve the effectiveness of selective thrombus aspiration.Entities:
Mesh:
Year: 2016 PMID: 27891513 PMCID: PMC5116489 DOI: 10.1155/2016/3823809
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Baseline characteristics.
| Parameters | Group I ( | Group II ( |
|
|---|---|---|---|
| Age (years, | 59 ± 11 | 56 ± 11 | 0.108 |
| Age ≧ 60 years | 16 (51.6) | 57 (33.3) | 0.051 |
| Gender, male, | 28 (90.3) | 149 (87.1) | 0.773 |
| Smoker, | 18 (58.1) | 115 (67.3) | 0.321 |
| Hypertension, | 24 (77.4) | 81 (47.4) | 0.002 |
| Diabetes, | 10 (32.3) | 35 (20.5) | 0.147 |
| History of PCI, | 1 (3.2) | 9 (5.3) | 1.000 |
| SBP (mmHg, | 116 ± 18 | 113 ± 15 | 0.437 |
| DBP (mmHg, | 73 ± 9 | 73 ± 10 | 0.771 |
| Killip classification, | 1.000 | ||
| 1~2 | 2 (6.5) | 14 (8.2) | |
| 3~4 | 29 (93.5) | 157 (91.8) | |
| WBC (×109/L) | 11.59 ± 2.77 | 11.31 ± 3.18 | 0.650 |
| Red cell count (×1012/L) | 4.58 ± 0.69 | 4.64 ± 0.53 | 0.573 |
| HBG (g/L) | 140.41 ± 19.66 | 143.37 ± 13.90 | 0.310 |
| Plt-count (×109/L) | 193.94 ± 50.30 | 203.05 ± 51.12 | 0.361 |
| PDW (%) | 12.97 ± 2.52 | 13.19 ± 2.85 | 0.736 |
| cTnI (ng/L) | 85.93 ± 69.73 | 89.65 ± 69.64 | 0.975 |
| ALT (U/L) | 60.84 ± 32.33 | 56.28 ± 41.33 | 0.310 |
| Scr ( | 83.92 ± 24.26 | 77.51 ± 18.82 | 0.099 |
| TG (mmol/L) | 1.81 ± 0.80 | 1.65 ± 1.03 | 0.138 |
| TCHO (mmol/L) | 4.68 ± 0.99 | 4.59 ± 0.97 | 0.639 |
| HDL-C (mmol/L) | 1.04 ± 0.23 | 0.98 ± 0.22 | 0.227 |
| LDL-C (mmol/L) | 3.01 ± 0.89 | 3.01 ± 0.88 | 0.983 |
| Admission GLU (mmol/L) | 9.15 ± 4.90 | 7.87 ± 2.70 | 0.179 |
P < 0.01; SBP, systolic blood pressure; DBP, diastolic blood pressure; HGB, hemoglobin, PDW, platelet distribution width; cTnI, cardiac troponin I; ALT, alanine transaminase; Scr, serum creatinine; TG, triglyceride; TCHO, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLU, glucose.
Figure 1ROC analysis of time from symptom to PCI for insufficient reperfusion (AUC 0.701, 95% CI: 0.605–0.797, P = 0.000).
Percutaneous intervention findings of patients with insufficient reperfusion and sufficient reperfusion.
| Parameters | Group I ( | Group II ( |
|
|---|---|---|---|
| Time from symptom to PCI (hour) | 6.2 ± 2.3 | 4.7 ± 2.3 | 0.000 |
| Time from symptom to PCI (≧4.8 hours) | 26 (83.9) | 70 (40.9) | 0.000 |
| Initial TIMI flow grade, | 0.107 | ||
| 0-1 | 28 (90.3) | 166 (97.1) | |
| ≥2 | 3 (9.7) | 5 (2.9) | |
| Multiple stents, | 0.746 | ||
| Yes | 8 (25.8) | 49 (28.7) | |
| No | 23 (74.2) | 122 (71.3) | |
| Multivessel disease, | 0.038† | ||
| Yes | 13 (41.9) | 41 (24.0) | |
| No | 18 (58.1) | 130 (76.0) | |
| IRA, | 0.183 | ||
| LAD | 10 (32.3) | 71 (41.5) | |
| LCX | 6 (19.4) | 15 (8.8) | |
| RCA | 15 (48.4) | 85 (49.7) | |
| Infarct location, | 0.363 | ||
| Anterior wall | 10 (32.3) | 70 (40.9) | |
| Nonanterior wall | 21 (67.7) | 101 (59.1) | |
| Initial degree of luminal stenosis (%) | 94.60 ± 17.63 | 98.10 ± 8.58 | 0.288 |
| Initial cTFC | 91.4 ± 22.8 | 94.3 ± 19.3 | 0.420 |
| Initial cTFC > 40, | 27 (87.1) | 160 (94.1) | 0.239 |
| Degree of postaspiration luminal stenosis (%) | 64.40 ± 22.94 | 67.66 ± 13.64 | 0.448 |
| Postaspiration TIMI 0, | 5 (16.1) | 5 (2.9) | 0.009 |
| Postaspiration cTFC | 55.5 ± 24.7 | 30.4 ± 17.0 | 0.000 |
| Postaspiration cTFC > 40, | 21 (67.7) | 29 (17.0) | 0.000 |
| GP IIb/IIIa inhibitor upfront used | |||
| Intracoronary GPII b/IIIa inhibitor, | 2 (6.5) | 15 (8.8) | 1.000 |
| Intravenous GP IIb/IIIa inhibitor, | 4 (12.9) | 25 (14.6) | 1.000 |
P < 0.01, † P < 0.05; IRA, infarct-related artery; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery.
Correlation between post-PCI cTFC and other parameters.
| Parameters |
|
|
|---|---|---|
| Initial cTFC | 0.015 | 0.832 |
| Postaspiration cTFC | 0.569 | 0.000 |
P < 0.01.
Figure 2ROC analysis of postaspiration cTFC for insufficient reperfusion (AUC 0.837, 95% CI: 0.766–0.908, P = 0.000).
Parameters postaspiration in patients with initial complete occlusion of IRA.
| Parameters | Insufficient reperfusion ( | Sufficient reperfusion ( |
|
|---|---|---|---|
| Postaspiration cTFC | 56.5 ± 24.8 | 30.5 ± 17.5 | 0.000 |
| Postaspiration cTFC > 40, | 16 (64.0) | 27 (17.3) | 0.000 |
| Postaspiration TIMI flow grade 0, | 4 (16.0) | 5 (3.2) | 0.022† |
P < 0.01, † P < 0.05.
Univariate and multivariate analysis in patients with TIMI thrombus 4~5 grade.
| Parameters | Univariate analysis | Stepwise multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age ≧ 60 years | 2.133 | 0.985–4.621 | 0.055 | 6.286 | 1.477–26.751 | 0.013† |
| Gender | 1.378 | 0.386–4.917 | 0.621 | 4.227 | 0.610–29.289 | 0.144 |
| Smoking | 1.483 | 0.679–3.241 | 0.323 | 0.717 | 0.185–2.771 | 0.629 |
| Diabetes | 1.850 | 0.799–4.285 | 0.151 | 0.758 | 0.159–3.614 | 0.728 |
| Hypertension | 3.810 | 1.558–9.312 | 0.003 | 7.235 | 1.864–28.076 | 0.004 |
| PCI history | 1.667 | 0.204–13.643 | 0.634 | 6.661 | 0.248–179.053 | 0.259 |
| Killip class ≧ 3 | 0.773 | 0.167–3.585 | 0.743 | 0.218 | 0.020–2.412 | 0.214 |
| WBC | 1.029 | 0.911–1.161 | 0.648 | 1.144 | 0.940–1.393 | 0.178 |
| Admission GLU | 1.108 | 0.999–1.229 | 0.052 | 1.115 | 0.889–1.400 | 0.346 |
| Time from symptom to PCI (≧4.8 hours) | 7.503 | 2.748–20.486 | 0.000 | 37.926 | 6.241–230.46 | 0.000 |
| Multivessel disease | 2.290 | 1.034–5.071 | 0.041† | 2.173 | 0.493–9.574 | 0.305 |
| Anterior wall infarction | 0.687 | 0.305–1.548 | 0.365 | 1.000 | 0.308–3.247 | 1.000 |
| Intracoronary GP IIb/IIIa inhibitor upfront used | 0.717 | 0.156–3.305 | 0.670 | 0.044 | 0.003–0.716 | 0.028† |
| Intravenous GP IIb/IIIa inhibitor upfront used | 0.865 | 0.279–2.685 | 0.802 | 3.359 | 0.491–22.984 | 0.217 |
| Initial cTFC > 40 | 0.422 | 0.123–1.442 | 0.169 | 0.513 | 0.065–4.034 | 0.526 |
| Degree of postaspiration luminal stenosis | 0.987 | 0.965–1.010 | 0.280 | 0.973 | 0.935–1.012 | 0.166 |
| Postaspiration cTFC > 40 | 10.283 | 4.384–24.116 | 0.000 | 29.273 | 6.557–130.685 | 0.000 |
P < 0.01, † P < 0.05.
Univariate and multivariate analysis in patients with initial TIMI flow grade 0~1.
| Parameters | Univariate analysis | Stepwise multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age ≧ 60 years | 2.329 | 1.036–5.234 | 0.041† | 9.123 | 1.948–42.710 | 0.005 |
| Gender | 1.273 | 0.354–4.574 | 0.711 | 3.940 | 0.558–27.837 | 0.169 |
| Smoking | 1.306 | 0.573–2.978 | 0.526 | 0.515 | 0.123–2.146 | 0.362 |
| Diabetes | 1.773 | 0.738–4.259 | 0.200 | 0.613 | 0.122–3.085 | 0.552 |
| Hypertension | 5.066 | 1.838–13.964 | 0.002 | 10.762 | 2.384–48.582 | 0.002 |
| PCI history | 1.548 | 0.188–12.715 | 0.684 | 4.732 | 0.151–148.102 | 0.376 |
| Killip class ≧ 3 | 0.835 | 0.179–3.891 | 0.819 | 0.390 | 0.040–3.761 | 0.415 |
| WBC | 1.031 | 0.909–1.169 | 0.638 | 1.133 | 0.925–1.388 | 0.229 |
| Admission GLU | 1.123 | 1.009–1.249 | 0.033† | 1.143 | 0.907–1.441 | 0.257 |
| Time from symptom to PCI (≧4.8 hours) | 6.467 | 2.343–17.847 | 0.000 | 43.917 | 6.554–294.287 | 0.000 |
| Multivessel disease | 1.973 | 0.855–4.553 | 0.111 | 1.831 | 0.382–8.770 | 0.449 |
| Anterior wall infarction | 0.666 | 0.284–1.560 | 0.349 | 0.862 | 0.260–2.862 | 0.809 |
| Intracoronary GP IIb/IIIa inhibitor upfront used | 0.835 | 0.179–3.891 | 0.819 | 0.150 | 0.013–1.736 | 0.129 |
| Intravenous GP IIb/IIIa inhibitor upfront used | 0.986 | 0.314–3.094 | 0.981 | 3.867 | 0.529–28.278 | 0.183 |
| Degree of postaspiration luminal stenosis | 0.990 | 0.966–1.014 | 0.407 | 0.973 | 0.935–1.012 | 0.166 |
| cTFC > 40 after aspiration | 10.405 | 4.268–23.365 | 0.000 | 27.005 | 5.757–126.669 | 0.000 |
P < 0.01; † P < 0.05.